Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Nicolò E, Tarantino P, D'Ecclesiis O, Antonarelli G, Boscolo Bielo L, Marra A, Gandini S, Crimini E, Giugliano F, Zagami P, Corti C, Trapani D, Morganti S, Criscitiello C, Locatelli M, Belli C, Esposito A, Minchella I, Cristofanilli M, Tolaney SM, Curigliano G. Nicolò E, et al. Among authors: belli c. Oncologist. 2024 Jan 5;29(1):75-83. doi: 10.1093/oncolo/oyad212. Oncologist. 2024. PMID: 37548439 Free PMC article. Review.
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M, Crimini E, Boscolo Bielo L, Guerini-Rocco E, Ascione L, Bonfanti A, Zanzottera C, Mazzarella L, Ranghiero A, Belli C, Criscitiello C, Esposito A, Barberis MCP, Curigliano G. Repetto M, et al. Among authors: belli c. Eur J Cancer. 2023 Apr;183:79-89. doi: 10.1016/j.ejca.2023.01.019. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801623
Variant allele frequency: a decision-making tool in precision oncology?
Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, Criscitiello C, Marra A, Subbiah V, Curigliano G. Boscolo Bielo L, et al. Among authors: belli c. Trends Cancer. 2023 Dec;9(12):1058-1068. doi: 10.1016/j.trecan.2023.08.011. Epub 2023 Sep 12. Trends Cancer. 2023. PMID: 37704501 Review.
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
Mazzarella L, Giugliano F, Nicolo E, Esposito A, Crimini E, Tini G, Uliano J, Corti C, D'Amico P, Aliaga PT, Valenza C, Repetto M, Antonarelli G, Ascione L, Vivanet G, Berton Giachetti P, Minchella I, Belli C, Locatelli M, Criscitiello C, Curigliano G. Mazzarella L, et al. Among authors: belli c. Oncologist. 2024 Feb 2;29(2):e266-e274. doi: 10.1093/oncolo/oyad239. Oncologist. 2024. PMID: 37715957 Free PMC article.
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Boscolo Bielo L, Repetto M, Crimini E, Belli C, Setola E, Parma G, Fusco N, Barberis M, Guerini Rocco E, Marra A, Colombo N, Curigliano G. Boscolo Bielo L, et al. Among authors: belli c. Oncologist. 2024 May 8:oyae082. doi: 10.1093/oncolo/oyae082. Online ahead of print. Oncologist. 2024. PMID: 38716772 Free article.
Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers.
Castelo L, da Silva WF, Lincango M, Buccheri V, Perusini A, Arbelbide J, Iastrebner M, Gonzalez J, Pereyra P, Pereira TDM, Marchi LL, Rocha V, Belli CB, Velloso EDRP. Castelo L, et al. Among authors: belli cb. Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00062-4. doi: 10.1016/j.clml.2024.02.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38462425 No abstract available.
196 results